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S U M M A R Y 
The susceptibility of the MAP Brazilian strain (F1 to F 5 progenies) of S. man¬ 
soni to four antischistosomal drugs has been reported in a previous study. In 
the present investigation, progeny F 1 4 of the same strain, was tested for stability 
to the same 4 drugs. A new medication, Oltipraz (35,972 R P ) , was added to the 
study. Five groups of 12 mice infected with cercariae by tail immersion were 
treated with hycanthone, oxamniquine, niridazole, praziquantel and Oltipraz. An 
untreated group was used as control. Schistosomal activity was assessed by the 
localization of worms in the portal vein system, by oogram changes, and per-
centage of parasite reduction. The stability of the susceptibility of progeny F 1 4 
did not change in relation to generations F1 to F 5; the progeny was resistant to 
hycanthone and oxamniquine; but sensitive to niridazole, praziquantel and Olti-
praz. We emphasize the importance of the phenomenon of resistance of the 
worm in view of the fact that oxamniquine has been widely used in Brazilian 
areas where mansonic schistosomiasis is endemic. 
I N T R O D U C T I O N 
The occurrence of resistant S. mansoni 
strains has been reported by several investiga-
tors 2. 3- 6. In a study on the behavior of a Bra-
zilian strain (MAP) of the worm towards schis-
tosomicidal drugs, were observed that progenies 
F1 to F 5 were resistant to oxamniquine and hy-
canthone but sensitive to niridazole and prazi-
quantel 3. The patient (MAP) from whom the 
strain was isolated was treated once with hy-
canthone and twice with oxamniquine, with no 
parasitologic cure. 
To evaluate the stability of the susceptibili-
ty of the MAP strain, an experimental thera-
peutic trial was carried out with the F 1 4 proge-
ny. 
In the present study we utilized a new drug, 
Oltipraz (35,972 R P ) , a new schistosomicidal 
drug that has been already tested in clinical 
trials 'A 
MATERIAL AND METHODS 
After a previous study, we have been main-
taining the MAP strain in our laboratory wi-
thout exposure to schistosomicidal drugs by the 
following transfer scheme: Biomphalaria gla-
brata — mice — Biomphalaria glabrata. 
F 1 4 Cercariae obtained from B. glabrata 
snails were used to infect female albino mice 
(Swiss), by the tail immersion technique9. 
Each mouse was exposed to 100 cercariae. Drug 
treatment was carried out as follows 45 days 
after cercarial infection: 1 x 80 mg/kg hycan-
thone, intramuscularly; 1 x 100 mg/kg oxamni-
quine; 5 x 100 mg/kg/day niridazole; 5 x 100 
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mg/kg/day praziquantel, and 5 x 125 mg/kg/day 
Oltipraz, orally. Each drug was applied to a 
different group of 12 mice. An untreated con­
trol group was formed to obtain miracidia for 
the next generation. 
The mice were killed with a blow on the 
neck 10 days after treatment and the worms 
recovered by perfusion 9. The schistosomicidal 
action was evaluated by the distribution of 
worms in the mesenteric vessels, percentage of 
mice with oogram changes and percentage of 
parasite reduction W . 
RESULTS 
We noticed that there was a high percen­
tage of male worms in almost all groups, spe­
cially in that treated with oxamniquine. We 
could also observe (Table I ) the existence of 
two different patterns obtained by the thera­
peutic evaluation. 
In the first pattern, represented by the 
groups treated with praziquantel, niridazole and 
Oltipraz we found a low percentage of worms 
in the mesenteric veins, 100% of altered 
oograms, and a high percentage of parasite re­
duction. 
In the second pattern, showed by the 
groups treated with hycanthone and oxamni­
quine, the findings consisted by a greater 
amount of worms in the mesenteric veins, no 
alterations in the oograms, and a low percen­
tage of parasite reduction. 
The data of the first pattern have demons­
trate some susceptibility to the antischistoso-
mal used against those groups of worms, by the 
other hand the results obtained in the second 
pattern were very similar to the control group, 
confirming the worm resistance to the oxam­
niquine and hycanthone. 
One of the most important criteria to be 
evaluated in experimental analysis of suscepti­
bility, in relation to antischistosomal drugs 
against S. mansoni is the percentage of para­
site reduction, since the surviving worms are 
the responsable by the therapeutic failure and 
potentially able to produce resistance progenies 
to this drugs 5. 1 0. 
Although cercarían infection was perform­
ed on groups of 12 mice, it was not always pos­
sible to treat the same number of animals be­
cause of mortality during the 45-day period 
proceeding drug administration. 
Worm mortality was not detected in the 
control group. 
DISCUSSION 
In the 14th progeny of the MAP strain, 
worm resistance remained stable when com­
pared to the 1st to 5th progeny with respect 
to hycanthone and oxamniquine. The strain also 
showed stability of the susceptibility to niri­
dazole and praziquantel. 
In the present study, Oltipraz, which was 
being used for the first time against the MAP 
strain, showed clear activity. No cross-resis­
tance with the other drugs studied here was 
shown by Oltipraz. 
An interesting fact occurred in the present 
experiment. A relatively high percentage of 
male worms occurred in the infections espe-
cialty in the group of mice treated with oxam-
niquine. Some investigators demonstrated that 
in infections by males only, most worms tend 
to be localized in the liver and portal vein n> 1 2. 
In the present study, although most of the 
worms were located in the liver and portal 
vein, in the animals treated with oxamniquine 
it could be seen that, when other parameters 
were utilized, the worms were resistant to the 
drug. However, the importance of well-balanced 
bisexual infections should be emphasized for 
the correct analysis of susceptibility to schis-
tosomicidal drugs when the criterion of worm 
distribution is used. 
CONCLUSIONS 
In conclusion, our results show that: ( a ) 
the resistance and susceptibility to four drugs 
of an S. mansoni strain were stable in the F M 
progeny "when compared to generations Pj to F 5; 
(b) a new drug, Oltipraz, tested only on proge-
ny F 1 4 , was shown to be effective, 'with no 
cross-resistance with hycanthone and oxamni-
quine. 
RESUMO 
Estabilidade de progênie de Schistosoma 
mansoni a drogas esquistossomicidas 
A suscetibilidade de linhagem brasileira 
( M A P ) , nas gerações F1 a F5 de S. mansoni a 
quatro drogas esquistossomicidas foi descrita 
em trabalho anterior. Na presente pesquisa os 
Autores testam a estabilidade da progênie F 1 4 
da referida linhagem às quatro drogas e a um 
novo medicamento, Oltipraz (35,972 R P ) . Cinco 
grupos de 12 camundongos infectados com cer-
carias por meio da imersão da cauda, foram 
tratados com hycanthone, oxamniquine, nirida¬ 
zole, praziquantel e Oltipraz. Foi utilizado um 
grupo controle de camundongos infectados e 
não tratados. A atividade esquistossomicida 
das drogas foi avaliada pela localização dos 
vermes no sistema porta, pelas alterações no 
oograma e percentagem de redução de vermes. 
A suscetibilidade dos vermes da geração F 1 4 
mostrou-se estável em relação àquelas observa-
das nas progénies F 1 a F 5; a progênie F 1 4 de 
vermes foi resistente ao hycanthone e oxamni-
quine; todavia, for sensível ao niridazole, prazi-
quantel e Oltipraz. Os Autores enfatizam a 
importância do fenômeno de resistência do ver-
me em vista do fato do oxamniquine ser larga-
mente utilizado em áreas do Brasil onde a es-
quistossomose mansônica é endêmica. 
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